Stefan Holdenrieder

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi Nucleosomal DNA fragments in autoimmune diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Ann N Y Acad Sci 1075:318-27. 2006
  2. ncbi Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, Ludwig Maximilians University, Marchioninistr 15, Munich, 81377, Germany
    Cancer Immunol Immunother 55:1584-9. 2006
  3. ncbi Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Munich, Germany
    Ann N Y Acad Sci 1075:244-57. 2006
  4. doi Clinical relevance of circulating nucleosomes in cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, Munich, Germany
    Ann N Y Acad Sci 1137:180-9. 2008
  5. ncbi Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich, Munich, Germany
    Clin Cancer Res 14:7813-21. 2008
  6. ncbi Clinical use of circulating nucleosomes
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital, Munich, Germany
    Crit Rev Clin Lab Sci 46:1-24. 2009
  7. ncbi Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, 81377 Munich, Germany
    Anticancer Res 27:2041-5. 2007
  8. ncbi Soluble MICA in malignant diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Ludwig Maximilians University, Munich, Germany
    Int J Cancer 118:684-7. 2006
  9. ncbi Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 30:1855-62. 2010
  10. ncbi Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Germany
    Cancer Biomark 6:179-90. 2010

Collaborators

Detail Information

Publications53

  1. ncbi Nucleosomal DNA fragments in autoimmune diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Ann N Y Acad Sci 1075:318-27. 2006
    ..It remains to be clarified whether qualitative changes in nucleosomes are linked with pathogenesis and disease progression in SLE...
  2. ncbi Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, Ludwig Maximilians University, Marchioninistr 15, Munich, 81377, Germany
    Cancer Immunol Immunother 55:1584-9. 2006
    ..While MICB levels are not suited for the diagnosis of cancer in early stages, they may provide additional information for the staging of cancer disease...
  3. ncbi Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Munich, Germany
    Ann N Y Acad Sci 1075:244-57. 2006
    ..Thus, nucleosomal DNA and CYFRA 21-1 specifically identify a subgroup of patients with insufficient therapy response at the early treatment phase and showed to be valuable for disease management...
  4. doi Clinical relevance of circulating nucleosomes in cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, Munich, Germany
    Ann N Y Acad Sci 1137:180-9. 2008
    ..Despite their non-tumor-specificity, kinetics of nucleosomes are valuable markers for the early estimation of therapeutic efficacy and may be helpful to adapting early cancer therapy in the future...
  5. ncbi Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich, Munich, Germany
    Clin Cancer Res 14:7813-21. 2008
    ..Besides new therapeutic drugs, effective diagnostic tools indicating early the efficacy of therapy are required to improve the individual management of patients with nonoperable cancer diseases...
  6. ncbi Clinical use of circulating nucleosomes
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital, Munich, Germany
    Crit Rev Clin Lab Sci 46:1-24. 2009
    ....
  7. ncbi Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, 81377 Munich, Germany
    Anticancer Res 27:2041-5. 2007
    ..In consequence, serum levels of soluble MICA and MICB are frequently found to be elevated in cancer disease...
  8. ncbi Soluble MICA in malignant diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Ludwig Maximilians University, Munich, Germany
    Int J Cancer 118:684-7. 2006
    ..015 and p = 0.007, respectively). While release of MICA is thought to impair tumor immunity, determination of sMICA levels may provide useful additional information in the diagnosis and staging of cancer...
  9. ncbi Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 30:1855-62. 2010
    ..Here, we investigated its relevance in diagnosis, therapy monitoring and prognosis of patients with diverse forms of lung cancer...
  10. ncbi Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Germany
    Cancer Biomark 6:179-90. 2010
    ....
  11. doi DNA integrity in plasma and serum of patients with malignant and benign diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich, Munich, Germany
    Ann N Y Acad Sci 1137:162-70. 2008
    ..In conclusion, we could not confirm a high diagnostic utility of the DNA integrity index. However, a combination with other markers such as DNA may enhance sensitivity for cancer detection...
  12. ncbi Circulating apoptotic markers in the management of non-small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich Grosshadern, Germany
    Cancer Biomark 6:197-210. 2010
    ..The review discusses their role for diagnosis, prognosis and therapy monitoring of lung cancer disease...
  13. ncbi Long-term stability of circulating nucleosomes in serum
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 30:1613-5. 2010
    ..Because many studies are carried out retrospectively on serum samples collected earlier, we tested the stability of nucleosomes during long-term storage at -70 degrees C...
  14. ncbi Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University of Munich, Munich, Germany
    Clin Cancer Res 10:5981-7. 2004
    ..We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in patients with advanced lung cancer...
  15. ncbi Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
    Michael Haas
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munich, Germany
    Tumour Biol 31:351-7. 2010
    ..86, p = 0.001) and CRP (HR 3.20, p = 0.001). Serum biomarker kinetics might serve as useful prognostic tools during second-line chemotherapy in advanced pancreatic cancer...
  16. doi Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich, Marchioninistr 15, D 81366 Munich, Germany
    Lung Cancer 63:128-35. 2009
    ..Thus, nucleosomes and CYFRA 21-1 showed to be valuable for the individual management of patients with recurrent NSCLC...
  17. doi Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
    Michael Haas
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munich, Germany
    J Cancer Res Clin Oncol 139:681-9. 2013
    ..CA 19-9 is the only established tumor marker in pancreatic cancer (PC); the prognostic role of other serum markers like CEA, CRP, LDH or bilirubin has not yet been defined...
  18. doi Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System
    Petra Stieber
    Institut fur Klinische Chemie, Klinikum der Universitat Munchen, Munich, Germany
    Clin Chem Lab Med 46:600-11. 2008
    ..Gastrointestinal cancer antigen CA19-9 is known as a valuable marker for the management of patients with pancreatic cancer...
  19. doi Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
    Christin Wittwer
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Int J Cancer 133:2619-30. 2013
    ..Thus, courses of circulating nucleosomes and immunogenic cell death markers HMGB1 and sRAGE show prognostic relevance in PC patients undergoing chemotherapy. ..
  20. ncbi Nucleosomes as a new prognostic marker in early cerebral stroke
    Sandra Geiger
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Marchioninistr 15, 81366, Munich, Germany
    J Neurol 254:617-23. 2007
    ..The prognostic relevance of blood markers in cerebral stroke is still a matter of controversial debate...
  21. doi Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
    Yvonne Nadine Fahmueller
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Germany
    Int J Cancer 132:2349-58. 2013
    ..HMGB1 is a valuable serum biomarker for early estimation of therapy response and prognosis in colorectal cancer patients with liver metastases undergoing RE therapy...
  22. doi Diagnostic relevance of plasma DNA and DNA integrity for breast cancer
    Oliver J Stötzer
    Hematology Oncology Outpatient Centre Munich, Munich, Germany
    Tumour Biol 35:1183-91. 2014
    ..4 and 95.5 %) and of MBC from all control groups by CA 15-3 and CEA (AUC 83.2 and 79.1 %). Plasma DNA is valuable for the detection of LBC, while established tumour markers are most informative in MBC...
  23. doi Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
    Oliver J Stoetzer
    Haematology and Oncology Outpatient Cancer Care Center, Franz Schrank Str 2, 80638, Munich, Germany
    Tumour Biol 34:81-90. 2013
    ..053). Markers of immunogenic cell death are valuable for the diagnosis of MBC and early estimation of response to neoadjuvant therapy in LBC patients...
  24. ncbi Nucleosomes in colorectal cancer patients during radiochemotherapy
    Andreas Kremer
    Institute of Clinical Chemistry, Klinikum der Universitat Munchen Grosshadern, Munich, Germany
    Tumour Biol 27:235-42. 2006
    ..In conclusion, the course of nucleosomes (AUC) might be valuable for the early prediction of therapy response in preoperatively treated colorectal cancer patients...
  25. pmc Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
    Susanne Mueller
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Marchioninistr, 15, D 81377 Munich, Germany
    BMC Cancer 6:143. 2006
    ..Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera of patients with malignant diseases...
  26. ncbi Nucleosomes in serum of patients with early cerebral stroke
    Sandra Geiger
    Institute of Clinical Chemistry, University of Munich, Munich, Germany
    Cerebrovasc Dis 21:32-7. 2006
    ..We investigated the kinetics of circulating nucleosomes after cerebral stroke and their correlation with the clinical status...
  27. ncbi Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy
    Julia Lehner
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Clin Chim Acta 425:206-11. 2013
    ..In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, biomarkers for predicting response to therapy are urgently required...
  28. doi Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy
    Nikolaus Kohles
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Tumour Biol 33:2401-9. 2012
    ..There was no difference with respect to treatment response for DNase and HMGB1. Soluble RAGE is a new parameter with predictive relevance in primary liver cancer patients undergoing TACE therapy...
  29. ncbi Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University of Munich, Munich, Germany
    Clin Chem 51:1544-6. 2005
  30. ncbi Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy
    Katharina Zeiss
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Anticancer Res 33:287-92. 2013
    ..The role of diabetes mellitus (DM) in the pathogenesis of pancreatic cancer (PC) and its prognostic role on patients with advanced disease remain undefined...
  31. pmc Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy
    Yvonne Nadine Fahmueller
    Institute of Clinical Chemistry, University Hospital, Munich Grosshadern, Germany
    BMC Cancer 12:5. 2012
    ..Markers for prediction of therapy response and prognosis are needed for the individual management of those patients undergoing SIRT...
  32. doi Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, Munich, Germany
    Clin Cancer Res 16:986-94. 2010
    ..The clinical relevance of CA 19-9 as surrogate biomarker in advanced pancreatic cancer is a matter of debate...
  33. pmc Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients
    Nikolaus Kohles
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Germany
    BMC Cancer 11:202. 2011
    ..Transarterial chemoembolization (TACE) therapy is an effective locoregional treatment in hepatocellular cancer (HCC) patients. For early modification of therapy, markers predicting therapy response are urgently required...
  34. ncbi Relevance of histone marks H3K9me3 and H4K20me3 in cancer
    Gloria Leszinski
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 32:2199-205. 2012
    ..While epigenetic and genetic modifications of DNA have been reported in blood of cancer patients, little is known about modifications of histones on circulating nucleosomes...
  35. ncbi Methodological and preanalytical evaluation of a RAGE immunoassay
    Christin Wittwer
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 32:2075-8. 2012
    ..Soluble receptor of advanced glycation end products (sRAGE) is a promising biomarker for the prognosis and the monitoring of cancer and of acute diseases such as trauma and sepsis...
  36. doi Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy
    Nikolaus Kohles
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Tumour Biol 33:33-40. 2012
    ..3 vs. 92.7). The combination of AFP, CHE, and LDH enables efficient pretherapeutic stratification of HCC patients in advanced tumor stage for TACE therapy...
  37. ncbi Nucleosomes in pancreatic cancer patients during radiochemotherapy
    Andreas Kremer
    Institute of Clinical Chemistry, Klinikum der Universitat Munchen Grosshadern, Munich, Germany
    Tumour Biol 26:44-9. 2005
    ..008). Our results indicate that the area under the curve of nucleosomes during the initial phase of radiochemotherapy could be valuable for the early prediction of the progression-free interval...
  38. ncbi Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy
    Stefan Holdenrieder
    Ludwig Maximilians University Munich, Klinikum Grosshadern, Munich, Germany
    Anticancer Res 25:1795-801. 2005
    ....
  39. ncbi Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 70:255-64. 2006
    ..It still remains to be defined whether the CA 19-9 response is a more reliable method for evaluating treatment efficacy compared to conventional imaging...
  40. ncbi Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 32:2179-83. 2012
    ..Circulating nucleosomes are elevated in the blood of patients with malignant and non-malignant diseases. Here, we investigated the nature and the dynamics of their release in functional cell studies...
  41. ncbi Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Brigitte Mahnert
    Institute of Clinical Chemistry, University of Munich, Munich, Germany
    Clin Chem Lab Med 41:104-10. 2003
    ..They cannot replace neither cystoscopy nor cytology. In the follow-up care more investigations may be necessary to prove the benefit of existing diagnostic strategies for the discrimination between active and inactive bladder cancer...
  42. ncbi Nucleosomes indicate the in vitro radiosensitivity of irradiated bronchoepithelial and lung cancer cells
    Stefan Holdenrieder
    Institute of Clinical Chemistry, Ludwig Maximilians University of Munich, Munich, Germany
    Tumour Biol 25:321-6. 2004
    ....
  43. ncbi Stability of nucleosomal DNA fragments in serum
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University of Munich, Munich, Germany
    Clin Chem 51:1026-9. 2005
  44. ncbi Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Onkologie 30:39-42. 2007
    ..CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information regarding survival of patients with metastatic PC...
  45. ncbi Methodological and preanalytical evaluation of an HMGB1 immunoassay
    Julia Lehner
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Anticancer Res 32:2059-62. 2012
    ..Soluble high-mobility group box 1 (sHMGB1) is a promising biomarker for the prognosis and the monitoring of cancer and of acute diseases such as trauma and sepsis...
  46. ncbi Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy
    Debora M I Fersching
    Institute of Clinical Chemistry, University Hospital Munich, Munich, Germany
    Anticancer Res 32:2047-58. 2012
    ..Neoadjuvant chemotherapy improves surgical options and prognosis in patients with operable breast cancer. Predictive biomarkers are needed to choose the most effective therapy and to avoid unnecessary toxicity...
  47. ncbi Does brain specific 24S-hydroxycholesterol in plasma indicate the disruption of the blood-brain barrier in patients with ischemic stroke?
    Stefan Holdenrieder
    Institute of Clinical Chemistry, Klinikum Grosshadern, Marchioninistrasse 15, University of Munich, D 81366 Munich, Germany
    Neurosci Lett 368:201-4. 2004
    ..Therefore, circulating levels of 24S-hydroxycholesterol are supposed to be only of limited value for monitoring the brain-blood barrier function in patients with acute ischemic stroke...
  48. doi Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System
    Stefan Holdenrieder
    Institut fur Klinische Chemie, Klinikum der Universitat Munchen, Munich, Germany
    Clin Chem Lab Med 46:588-99. 2008
    ..Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer...
  49. doi Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases
    Steffen Massberg
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    Nat Med 16:887-96. 2010
    ..The ability of coagulation to suppress pathogen dissemination indicates that microvessel thrombosis represents a physiological tool of host defense...
  50. ncbi Soluble NKG2D ligands: prevalence, release, and functional impact
    Helmut Rainer Salih
    Department of Internal Medicine II, Eberhard Karls University, Tuebingen, Germany
    Front Biosci 13:3448-56. 2008
    ..Here we review and discuss the available data on the prevalence, release, functional impact, and potential clinical value of sNKG2DL...
  51. ncbi Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay
    Thomas Muley
    Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
    Clin Chem Lab Med 41:95-103. 2003
    ..The special merits of this new assay are the wide measuring range (according to manufacturer's declaration up to 370 ng/ml) and a short incubation time of 18 min...
  52. doi Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System
    Rafael Molina
    Laboratory for Clinical Biochemistry and Molecular Genetics, Hospital Clinic, Barcelona, Spain
    Clin Chem Lab Med 46:612-22. 2008
    ..Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer...
  53. ncbi New horizons for diagnostic applications of circulating nucleosomes in blood?
    Stefan Holdenrieder
    Clin Chem 54:1104-6. 2008